Home > Newsletters > FDAnews Drug Daily Bulletin > Reducing Non-Core Trial Procedures Could Save Billions: Tufts Researcher
FDAnews Drug Daily Bulletin
July 20, 2012 | Vol. 9 No. 142
Reducing Non-Core Trial Procedures Could Save Billions: Tufts Researcher
Drugmakers are paying anywhere from $3 billion to $5 billion annually for clinical trial procedures that may not be necessary, a new study concludes. Roughly 25 percent of typical clinical trial protocols and 20 percent of trial budgets are dedicated to non-core trial procedures — those that are not directly linked to a primary or key secondary endpoint needed to demonstrate the drug’s safety or efficacy.
Clinical Trials Advisor
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.